News
-
-
COMMUNIQUÉ DE PRESSE
Knorr-Bremse fully on track: Strong rail business and further improvement in profitability
Knorr-Bremse AG reports strong performance in Q3 2025 with €6.4 billion order intake, €5.8 billion revenues, and 12.8% operating EBIT margin. Emphasis on rail business and profitability improvement -
COMMUNIQUÉ DE PRESSE
HelloFresh SE Delivers Robust Efficiency Gains and Strong YTD Cash Flow in Q3 2025; Accelerates Product Investment Strategy
HelloFresh SE reports robust efficiency gains and strong YTD cash flow in Q3 2025, accelerating product investment strategy. Consolidated revenue declines year-on-year but AOV increases. Group maintains solid financial position -
-
COMMUNIQUÉ RÉGLEMENTÉ
Recticel Trading update third quarter 2025 - Continued Volume Growth
Recticel reports continued organic volume growth in Q3 2025 despite drop in sales due to lower raw material costs. Strategic acquisitions and investments aim to boost high added value products. CEO optimistic about future market trends -
-
COMMUNIQUÉ DE PRESSE
KION with a solid third quarter – strong order intake increase in the first nine months of 2025
KION reports solid third quarter results with strong order intake growth in the first nine months of 2025. Revenue slightly down, adjusted EBIT margin at 7.0%. Outlook revised for free cash flow and efficiency program expenses -
COMMUNIQUÉ DE PRESSE
Avolta 9M 2025 delivers another set of strong results with record EFCF and deleverages to 1.9x
Avolta reports strong 9M 2025 financial results, achieving record EFCF and deleveraging to 1.9x. Company maintains robust performance with +5.4% organic growth and 10.2% CORE EBITDA margin -
COMMUNIQUÉ DE PRESSE
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Formycon AG to discuss 2025 Nine-Month Results in Conference Call and participate in Investor Conferences. Company specializes in biosimilars for various disease areas -
COMMUNIQUÉ DE PRESSE
Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
Piramal Pharma Solutions partners with IntoCell to enhance bioconjugate capabilities and ADC development. Strategic agreement strengthens competitive edge and accelerates bioconjugate services
